AUSTIN, Texas, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat genetic rare diseases and cancer, today announced that it will present preclinical results from studies evaluating AEB3103, which targets a vulnerability of cancer metabolism for the treatment of hematological malignancies, at the 58 th Annual American Society of Hematology (ASH) Meeting being held December 3-6, 2016 in San Diego, California. Treatment with AEB3103, an engineered human enzyme that degrades the amino acid cysteine/cystine resulting in selective oxidative stress for malignant cells, demonstrated in preclinical studies an increased median survival time in a mouse model of chronic lymphocytic leukemia (CLL) compared with an approved front line therapy, fludarabine. Additionally, treatment with AEB3103 inhibited cell growth in several models, including in vitro cultures of patient-derived CLL and multiple myeloma cells, as well as ex vivo cultures of patient-derived acute lymphocytic leukemia and acute myeloid leukemia cells. Full abstracts are available online at www.hematology.org. Details of the upcoming poster presentation are listed below. Abstract Title (#1587): Development of a human therapeutic L-Cyst(e)ine-degrading enzyme for the treatment of hematological malignancies Session Title: 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster I Date: Saturday, December 3, 2016 Presentation Time: 5:30 p.m. - 7:30 p.m. PT Location: San Diego Convention Center, Hall GH About Aeglea BioTherapeuticsAeglea is a biotechnology company committed to developing engineered human enzymes for the treatment of rare diseases and cancer associated with abnormal amino acid metabolism. The company's engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in genetic rare diseases or to starve tumors dependent on amino acids by reducing levels below the normal range. Aeglea's clinical program for its lead product candidate, AEB1102, includes three Phase 1 clinical trials, studying AEB1102 for the treatment of patients with Arginase I deficiency, advanced solid tumors and hematological malignancies. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for a genetic rare disease, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine. For more information, visit http://aegleabio.com.
Media Contact:Kelly Boothe, Ph.D.BrewLife415.email@example.comInvestor Contact:Charles N. York IIChief Financial OfficerAeglea BioTherapeuticsinvestors@aegleabio.com